1	8 if felbamate be use as a concomitant aed participant must be on felbamate for at least 2 year with a stable dose for 8 week prior to visit 1 they must not have a history of white blood cell wbc count below 2500/l 2.50 x 10^9/l platelet below 100,000 liver function test lfts above 3 time the|felbamate[5,14]|||||||||C0060135|24812|24812|felbamate
1	8 if felbamate be use as a concomitant aed participant must be on felbamate for at least 2 year with a stable dose for 8 week prior to visit 1 they must not have a history of white blood cell wbc count below 2500/l 2.50 x 10^9/l platelet below 100,000 liver function test lfts above 3 time the|felbamate[66,75]||||2.50[215,219]||x 10[220,224]|8 week[119,125]||C0060135|24812|24812|felbamate
2	upper limit of normal uln or other indication of hepatic or bone marrow dysfunction while receive felbamate if participant receive felbamate in the past it must have be discontinue 8 week prior to visit 1|felbamate[392,401]|||||||8 week[475,481]||C0060135|24812|24812|felbamate
2	upper limit of normal uln or other indication of hepatic or bone marrow dysfunction while receive felbamate if participant receive felbamate in the past it must have be discontinue 8 week prior to visit 1|felbamate[425,434]|||||||||C0060135|24812|24812|felbamate
